Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Market Cap: US$2.0b

Mirum Pharmaceuticals Valuation

Is MIRM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MIRM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MIRM ($42.21) is trading below our estimate of fair value ($182.16)

Significantly Below Fair Value: MIRM is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MIRM?

Other financial metrics that can be useful for relative valuation.

MIRM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.7x
Enterprise Value/EBITDA-22.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MIRM's PS Ratio compare to its peers?

The above table shows the PS ratio for MIRM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
BEAM Beam Therapeutics
6.4x-11.9%US$2.4b
ARDX Ardelyx
4.3x25.6%US$1.2b
IMCR Immunocore Holdings
5.7x13.8%US$1.7b
PTGX Protagonist Therapeutics
7.9x-8.4%US$2.8b
MIRM Mirum Pharmaceuticals
7.6x25.7%US$2.0b

Price-To-Sales vs Peers: MIRM is expensive based on its Price-To-Sales Ratio (7.6x) compared to the peer average (6.1x).


Price to Earnings Ratio vs Industry

How does MIRM's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: MIRM is good value based on its Price-To-Sales Ratio (7.6x) compared to the US Biotechs industry average (12.4x).


Price to Sales Ratio vs Fair Ratio

What is MIRM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MIRM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.6x
Fair PS Ratio7.8x

Price-To-Sales vs Fair Ratio: MIRM is good value based on its Price-To-Sales Ratio (7.6x) compared to the estimated Fair Price-To-Sales Ratio (7.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MIRM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$42.21
US$59.91
+41.9%
17.6%US$71.00US$39.00n/a11
Nov ’25US$40.40
US$59.45
+47.2%
17.2%US$71.00US$39.00n/a11
Oct ’25US$40.12
US$59.27
+47.7%
17.6%US$71.00US$39.00n/a11
Sep ’25US$43.11
US$59.27
+37.5%
17.6%US$71.00US$39.00n/a11
Aug ’25US$40.13
US$57.18
+42.5%
19.7%US$71.00US$39.00n/a11
Jul ’25US$34.16
US$57.09
+67.1%
19.6%US$71.00US$39.00n/a11
Jun ’25US$24.03
US$48.00
+99.8%
22.2%US$66.00US$31.00n/a11
May ’25US$25.72
US$48.91
+90.2%
24.9%US$72.00US$33.00n/a11
Apr ’25US$25.45
US$49.00
+92.5%
26.0%US$72.00US$33.00n/a10
Mar ’25US$29.27
US$47.20
+61.3%
25.3%US$69.00US$33.00n/a10
Feb ’25US$26.59
US$48.10
+80.9%
25.6%US$64.00US$33.00n/a10
Jan ’25US$29.52
US$48.30
+63.6%
25.4%US$64.00US$33.00n/a10
Dec ’24US$32.00
US$54.70
+70.9%
25.5%US$78.00US$37.00n/a10
Nov ’24US$28.42
US$57.71
+103.1%
22.7%US$77.00US$38.00US$40.407
Oct ’24US$31.60
US$59.20
+87.3%
29.9%US$84.00US$35.00US$40.125
Sep ’24US$26.44
US$56.50
+113.7%
33.3%US$84.00US$35.00US$43.114
Aug ’24US$24.97
US$56.25
+125.3%
31.9%US$82.00US$35.00US$40.134
Jul ’24US$25.87
US$54.43
+110.4%
33.5%US$81.00US$34.00US$34.167
Jun ’24US$26.11
US$51.38
+96.8%
36.7%US$81.00US$30.00US$24.038
May ’24US$26.99
US$51.38
+90.3%
36.7%US$81.00US$30.00US$25.728
Apr ’24US$24.02
US$51.63
+114.9%
37.3%US$83.00US$30.00US$25.458
Mar ’24US$23.70
US$51.88
+118.9%
37.4%US$84.00US$30.00US$29.278
Feb ’24US$23.88
US$52.88
+121.4%
37.9%US$84.00US$30.00US$26.598
Jan ’24US$19.50
US$54.75
+180.8%
36.9%US$88.00US$30.00US$29.528
Dec ’23US$18.28
US$55.88
+205.7%
36.7%US$88.00US$30.00US$32.008
Nov ’23US$23.09
US$56.63
+145.2%
35.1%US$88.00US$31.00US$28.428

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies